Display options
Cite
Giordani L, Sandoná M, Rotini A, et al. Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies. Rare Dis. 2014;2(1):e974969doi: 10.4161/21675511.2014.974969.
Giordani, L., Sandoná, M., Rotini, A., Puri, P. L., Consalvi, S., & Saccone, V. (2014). Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies. Rare diseases (Austin, Tex.), 2(1), e974969. https://doi.org/10.4161/21675511.2014.974969
Giordani, L, et al. "Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies." Rare diseases (Austin, Tex.) vol. 2,1 (2014): e974969. doi: https://doi.org/10.4161/21675511.2014.974969
Giordani L, Sandoná M, Rotini A, Puri PL, Consalvi S, Saccone V. Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies. Rare Dis. 2014 Dec 01;2(1):e974969. doi: 10.4161/21675511.2014.974969. eCollection 2014. PMID: 26942105; PMCID: PMC4755242.
Copy Download .nbib Format: NLM
Share it on

Rare Dis. 2014 Dec 01;2(1):e974969. doi: 10.4161/21675511.2014.974969. eCollection 2014.

Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies.

Rare diseases (Austin, Tex.)

L Giordani, M Sandoná, A Rotini, P L Puri, S Consalvi, V Saccone

Affiliations

  1. Sanford-Burnham Medical Research Institute; Sanford Children's Health; Research Center , La Jolla, CA USA.
  2. IRCCS Fondazione Santa Lucia , Rome, Italy.
  3. Sanford-Burnham Medical Research Institute; Sanford Children's Health; Research Center, La Jolla, CA USA; IRCCS Fondazione Santa Lucia, Rome, Italy.

PMID: 26942105 PMCID: PMC4755242 DOI: 10.4161/21675511.2014.974969

Abstract

Recent studies have revealed the contribution of fibro-adipogenic progenitors (FAPs) to the pathogenesis and progression of Duchenne Muscular Dystrophy (DMD). While FAPs direct compensatory regeneration at early stages of disease, as the disease progresses they contribute to the progressive replacement of contractile myofibers with fibrotic scars and fatty infiltration. Using the mouse model of DMD - the mdx mice - we have recently reported that FAPs mediate the ability of HDAC inhibitors (HDACi) to promote muscle regeneration and prevent fibro-adipogenic degeneration at early stages of disease. This effect is mediated by the induction of myomiRs that, in turn, target the SWI/SNF components BAF60A and B, thereby favoring the formation of BAF60C-based SWI/SNF complex, which directs the switch from the fibro-adipogenic to the myogenic lineage. Here we show direct evidence of induction of miR-206 and BAF60C, and reduction of BAF60A, in FAPs isolated from mdx muscles exposed to the HDACi Trichostatin A (TSA). We also discuss how increased expression of myomiRs in dystrophic muscles can be integrated with circulating myomiRs to provide accurate biomarkers of disease progression and response to treatment.

Keywords: BAF60; DMD; FAPs; diagnostic biomarkers; myomiRs

References

  1. Pediatr Dev Pathol. 2006 Nov-Dec;9(6):427-43 - PubMed
  2. Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19183-7 - PubMed
  3. Nat Cell Biol. 2011 Apr;13(4):423-33 - PubMed
  4. Hum Mol Genet. 2012 Jun 1;21(11):2559-71 - PubMed
  5. EMBO Mol Med. 2011 May;3(5):258-65 - PubMed
  6. J Neuropathol Exp Neurol. 2009 Jul;68(7):762-73 - PubMed
  7. Cell. 2013 Apr 11;153(2):376-88 - PubMed
  8. Cell Cycle. 2014;13(1):78-89 - PubMed
  9. Nat Cell Biol. 2010 Feb;12(2):143-52 - PubMed
  10. Genes Dev. 2014 Apr 15;28(8):841-57 - PubMed
  11. J Stem Cell Res Ther. 2012 Oct 17;(Suppl 11):null - PubMed
  12. Neuron. 2007 Jul 19;55(2):201-15 - PubMed
  13. Nat Med. 2006 Oct;12(10):1147-50 - PubMed
  14. Nucleic Acids Res. 2013 Nov;41(20):9500-13 - PubMed
  15. Cell Metab. 2008 Aug;8(2):105-17 - PubMed
  16. J Am Soc Nephrol. 2013 Feb;24(3):385-92 - PubMed
  17. Cell Metab. 2010 Oct 6;12(4):341-51 - PubMed
  18. EMBO J. 2012 Jan 18;31(2):301-16 - PubMed
  19. Nat Rev Genet. 2006 Jun;7(6):461-73 - PubMed
  20. Curr Opin Genet Dev. 2003 Jun;13(3):231-8 - PubMed
  21. Nat Genet. 2004 Jul;36(7):738-43 - PubMed
  22. PLoS One. 2014 Feb 19;9(2):e89237 - PubMed
  23. J Cell Biol. 2006 Aug 28;174(5):677-87 - PubMed
  24. Cell Rep. 2013 Mar 28;3(3):661-70 - PubMed
  25. Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4525-9 - PubMed
  26. Curr Top Dev Biol. 2011;96:167-201 - PubMed
  27. PLoS One. 2013;8(2):e55281 - PubMed
  28. Curr Opin Cell Biol. 2009 Jun;21(3):461-9 - PubMed
  29. Nature. 2011 Jul 13;476(7359):228-31 - PubMed
  30. J Cell Mol Med. 2009 Jan;13(1):2-11 - PubMed
  31. EMBO Mol Med. 2013 Apr;5(4):626-39 - PubMed
  32. Development. 2014 Sep;141(17):3378-87 - PubMed
  33. Genes Dev. 2012 Dec 15;26(24):2673-83 - PubMed
  34. PLoS One. 2011 Mar 30;6(3):e18388 - PubMed
  35. Cell. 2009 Jan 23;136(2):200-6 - PubMed
  36. Biochim Biophys Acta. 2012 Jul;1820(7):940-8 - PubMed
  37. Biol Proced Online. 2014 Mar 14;16(1):5 - PubMed
  38. Nat Genet. 2006 Feb;38(2):228-33 - PubMed
  39. FASEB J. 2014 Jun;28(6):2603-19 - PubMed
  40. Genes Dev. 1996 Sep 1;10(17):2117-30 - PubMed
  41. FASEB J. 2009 Oct;23(10):3335-46 - PubMed
  42. Genes Dev. 2005 Oct 1;19(19):2343-54 - PubMed
  43. Mol Med. 2013 May 20;19:79-87 - PubMed
  44. FEBS J. 2013 Sep;280(17):4100-8 - PubMed
  45. Mol Ther Nucleic Acids. 2012 Aug 14;1:e39 - PubMed
  46. Nature. 2004 Nov 4;432(7013):107-12 - PubMed
  47. J Cell Sci. 2011 Nov 1;124(Pt 21):3654-64 - PubMed
  48. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  49. Nat Cell Biol. 2010 Feb;12(2):153-63 - PubMed
  50. PLoS Curr. 2013 Sep 17;5:null - PubMed
  51. FEBS J. 2013 Sep;280(17):4014-25 - PubMed

Publication Types